CRISM Therapeutics Corporation

CRTX

VGG042401262

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:21 2024-07-17 am EDT			5-day change	1st Jan Change
13.5 ^GBX	0.00%		-6.90%	-6.25%

Jul. 04	Crism Therapeutics Affirms Plan to File Clinical Trial Application for Lead Product in H2	MT
Jul. 03	Crism flags contract talks, reacts to share price surge	AN

Amur Minerals Corporation Announces Appointment of Thomas Bowens as Non-Executive Director

August 07, 2019 at 02:00 am EDT

Amur Minerals Corporation announced that the company has appointed Mr. Thomas Bowens to the Board as a Non-Executive Director, with immediate effect. Mr. Bowens has over 25 years of international experience in the minerals exploration sector and is the President and CEO of IG Copper, a company he founded in 2009. IG Copper held the exploration and mining licences for the Malmyzh copper-gold porphyry project. Thomas has degrees in Economics, Geological Engineering (Magna Cum Laude) and a Master's degree in Geology, the latter two from the Colorado School of Mines.

Latest news about CRISM Therapeutics Corporation

Crism Therapeutics Affirms Plan to File Clinical Trial Application for Lead Product in H2	Jul. 04	MT
Crism flags contract talks, reacts to share price surge	Jul. 03	AN
Crism has first day of trade on AIM after name change, buy	May. 31	AN
Amur Minerals confirms Extruded buy, name change and board shake-up	May. 29	AN
Amur Minerals agrees reverse takeover of Extruded Pharma	May. 13	AN
Amur Minerals Signs Reverse Takeover Deal With Extruded Pharmaceuticals	May. 13	MT
Amur Minerals Corporation executed a share and purchase agreement to acquire Extruded Pharmaceuticals Ltd for £5.5 million.	May. 12	CI
Amur Minerals swings to profit in 2023 as costs fall	May. 10	AN
Amur Minerals Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	May. 10	CI
EARNINGS AND TRADING: Impairment charge pushes Quartix into the red	Mar. 04	AN
Amur Minerals Advances Reverse Takeover Deal	Mar. 04	MT
Amur Minerals reports widened interim loss as reviews opportunities	23-09-25	AN
Amur Minerals Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-25	CI
Amur Minerals Corporation Announces Special Dividend	23-09-25	CI
Tintra receives bid approach; NCC trading in line	23-09-07	AN
FTSE 100 Closes Up 0.21% on Pound Weakness	23-09-07	DJ
UK Inflation Expectations Fall, Boosting Prospects for BOE Rate Pause	23-09-07	DJ
UK Gilt Yields Fall on Rising Expectations of a BOE Rate Pause	23-09-07	DJ
FTSE 100 Falls After Weak Performance in Asian Markets	23-09-07	DJ
Amur Minerals Shares Cease Trading on London Bourse's AIM Submarket	23-09-07	MT
Amur Minerals Notes AIM’s Reverse Takeover Requirement	23-08-15	MT
FTSE 100 Closes Down as Investors Driven into Risk-Off Mood	23-08-08	DJ
Sterling Likely to Fall in Longer Run as Markets Overestimate Rate Prospects	23-08-08	DJ
Amur Minerals ends discussions over possible Ascent Resources takeover	23-08-08	AN
FTSE 100 Edges Lower as Miners Fall After Weak China Trade Data, Glencore Earnings	23-08-08	DJ

Chart CRISM Therapeutics Corporation

Duration

Period

More charts

Company Profile

CRISM Therapeutics Corporation, formerly Amur Minerals Corporation, is a British Virgin Islands-based pharmaceutical company. The Company has developed a drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy. Its lead product, ChemoSeed, is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumor or the resection margin following the removal of a tumor, thereby ensuring that effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. It seeks to use ChemoSeed to treat high grade gliomas, a brain tumor with no satisfactory treatment. The Company also offers formulation and consultancy services. It provides assistance and services to improve the bioavailability of poorly soluble drugs. It offers remixers and extruders of various sizes.

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRISM THERAPEUTICS CORPORATION	-6.25%	1.52M
ELI LILLY AND COMPANY	+55.98%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.04%	363B
MERCK & CO., INC.	+15.43%	318B
ABBVIE INC.	+13.00%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.40%	179B
PFIZER, INC.	+4.10%	167B